COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Initiation and Titration of Amaryl (AMIT KZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01144728
Recruitment Status : Completed
First Posted : June 16, 2010
Last Update Posted : January 31, 2011
Information provided by:

Brief Summary:

Primary Objective:

  • To describe the conditions of initiation and titration of Amaryl M, according to previous treatment:
  • initial dose
  • titration scheme
  • efficacy after 4 months assessed by HbA1C
  • tolerability (number and severity of hypoglycaemia)

Secondary Objective:

  • Fasting Plasma Glucose
  • Weight evolution

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Drug: GLIMEPIRIDE + METFORMIN Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 172 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: AMIT Study - Amaryl M Initiation and Titration Study
Study Start Date : May 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Single arm Glimepiride+metformin
Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.
Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500

Primary Outcome Measures :
  1. Glycolysated Haemoglobin (HbA1c) [ Time Frame: From baseline to Month 4 ]
  2. Patients With Glycosylated Haemoglobin (HbA1c) Value < 7% [ Time Frame: Month 4 ]
  3. Evolution of Fasting Plasma Glucose (FPG) [ Time Frame: From baseline to Months 4 ]

Secondary Outcome Measures :
  1. Post Prandial Plasma Glucose (PPPG) [ Time Frame: Month 4 ]
  2. Number of patients for each start dose [ Time Frame: At baseline ]
  3. Number of patients with different final doses [ Time Frame: Month 4 ]
  4. Rate of Symptomatic Hypoglycemia [ Time Frame: During treatment period (4 months) ]
  5. Change in Weight [ Time Frame: Month 4 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Patients with Type 2 diabetes who have been treated with a stable dose (any dose) of :
  • sulfonylurea monotherapy or
  • metformin monotherapy or
  • free combination of glimepiride and metformin with a stable dose (any dose)
  • Body Mass Index (BMI) between 20 and 40 kg/m2
  • HbA1c superior or egal to 7.5%
  • FPG superior or egal 7 mmol/l

Exclusion criteria:

  • Secondary or insulin-dependant diabetes
  • Any severe chronic disease (hepatic, renal impairments)
  • History of major cardiovascular event in the last 6 months
  • Acute conditions with the potential to alter renal function such as: dehydratation, severe infection, shock, IV administration of iodinated contrast agents
  • Allergy to sulfonylurea, metformin
  • Drug or alcohol abuse
  • Pregnancy, lactation

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01144728

Layout table for location information
Sanofi-Aventis Administrative Office
Almaty, Kazakhstan
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Trial Transparency Team, sanofi-aventis Identifier: NCT01144728    
Other Study ID Numbers: GLMET_L_04718
U1111-1116-9956 ( Other Identifier: UTN )
First Posted: June 16, 2010    Key Record Dates
Last Update Posted: January 31, 2011
Last Verified: January 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Immunosuppressive Agents
Immunologic Factors